{
    "nctId": "NCT03368196",
    "briefTitle": "DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein",
    "officialTitle": "Phase 1, Multicenter, Open-label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2-Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Adenocarcinoma, Gastric, Neoplasm, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "Treatment-emergent Adverse Events Following Treatment With DS-8201a (Trastuzumab Deruxtecan)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Has a pathologically documented unresectable or metastatic gastric or GEJ adenocarcinoma, or breast cancer, with HER2 expression \\[immunohistochemistry (IHC) 3+, 2+, or 1+ and/or in situ hybridization (ISH) +\\] that is refractory to or intolerable with standard treatment, or for which no standard treatment is available\n* Has a left ventricular ejection fraction (LVEF) \u2265 50%\n* Has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1\n\nExclusion Criteria:\n\n* Has a medical history of myocardial infarction within 6 months before enrollment\n* Has a medical history of ventricular arrhythmias, other than rare occasional premature ventricular contractions\n* Has uncontrolled or significant cardiovascular disease\n* Has any other history or condition that might compromise:\n\n  1. Safety of the participant or offspring\n  2. Safety of study staff\n  3. Analysis of Results",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}